Barclays Maintains Overweight on Ligand Pharmaceuticals, Lowers Price Target to $150
Barclays analyst Balaji Prasad maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight and lowers the price target from $157 to $150.
Avista Public Acquisition Corp. II And OmniAb Business Combination Approved By APAC Shareholders Closing Scheduled for November 1;
APAC Shareholder Approval Obtained, Closing Scheduled for November 1, 2022
Ligand "Regular Way" and "Ex-Distribution" and OmniAb "When-Issued" Set to Begin Trading on October 25,
Sermonix Pharmaceuticals Shares Additional Findings From Its Evaluation Of Lasofoxifene In ESR1 Mutations Phase 2 Study At The 4th Annual Congress Of The ISLB NOTE: Sermonix Licensed Lasofoxifene Globally From Ligand Pharmaceuticals
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today shared additional
Ligand Announces Record Date And Details For Distribution For OmniAb Spin-Off
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for the dividend of shares of common stock of OmniAb, Inc. to
Ligand Pharmaceuticals Licensor Of Sermonix Pharmaceuticals Shares Details Of Durable Complete Clinical Response In A Metastatic ER+/HER2- Breast Cancer Patient With An ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Ba…
Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah
Roth Capital Maintains Buy on Ligand Pharmaceuticals, Lowers Price Target to $175
Roth Capital analyst Scott Henry maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and lowers the price target from $185 to $175.
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene…
Ligand Pharmaceuticals Sees FY22 Royalties $62M-$66M
2022 Financial Guidance
Ligand is raising 2022 revenue guidance for the combined business and is reaffirming revenue estimated to be attributable to the OmniAb business anticipating the spin-off occurs
Stephens & Co. Maintains Overweight on Ligand Pharmaceuticals, Lowers Price Target to $130
Stephens & Co. analyst Jacob Johnson maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight and lowers the price target from $153 to $130.